一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。 - Suppr

Suppr

超能文献

Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.

作者信息

Aboul-Fettouh Nader, Nijhawan Rajiv I

机构信息

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.

出版信息

JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.

DOI:10.1016/j.jdcr.2018.01.001

PMID:29984281

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6031591/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febd/6031591/6f4da4eadf2e/gr1.jpg

相似文献

Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。

JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.使用鲁索替尼治疗的患者中快速生长且侵袭性强的皮肤鳞状细胞癌

Ann Dermatol. 2019 Apr;31(2):204-208. doi: 10.5021/ad.2019.31.2.204. Epub 2019 Feb 28.

Janus kinase inhibitors: jackpot or potluck?Janus激酶抑制剂：是意外之喜还是碰运气？

Oncol Rev. 2012 Jun 20;6(1):e13. doi: 10.4081/oncol.2012.e13. eCollection 2012 Mar 5.

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.用于治疗炎症性和肿瘤性疾病的 Janus 激酶（JAK）抑制剂

Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.用于伴发真性红细胞增多症的Janus激酶抑制剂治疗后皮肤结节病的消退

JAAD Case Rep. 2019 Apr 5;5(4):360-361. doi: 10.1016/j.jdcr.2019.02.006. eCollection 2019 Apr.

Frequent Urinary Tract Infections in a Patient Treated with Ruxolitinib.接受鲁索替尼治疗的患者频繁发生尿路感染。

Antibiotics (Basel). 2019 Sep 16;8(3):150. doi: 10.3390/antibiotics8030150.

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.在Janus激酶抑制剂时代减轻骨髓增殖性肿瘤患者的症状负担

Leuk Lymphoma. 2015 Jul;56(7):1989-99. doi: 10.3109/10428194.2014.983098. Epub 2015 Mar 17.

A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib.一名服用鲁索替尼的患者出现光分布性丘疹脓疱性皮疹和多发性鳞状细胞癌。

JAAD Case Rep. 2019 Oct 22;5(10):895-897. doi: 10.1016/j.jdcr.2019.06.038. eCollection 2019 Oct.

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.1例在用Janus激酶抑制剂托法替布治疗期间发生的伴有淋巴管浸润的侵袭性鳞状细胞癌。

JAAD Case Rep. 2020 Jun 16;6(8):727-730. doi: 10.1016/j.jdcr.2020.06.008. eCollection 2020 Aug.

Development of sebaceous carcinoma in a patient on ruxolitinib therapy.一名接受鲁索替尼治疗的患者发生皮脂腺癌。

JAAD Case Rep. 2022 Jun 13;26:17-19. doi: 10.1016/j.jdcr.2022.05.033. eCollection 2022 Aug.

引用本文的文献

Merkel cell carcinoma in collision with squamous cell carcinoma and basal cell carcinoma in a patient on ruxolitinib treatment for myeloproliferative neoplasm.一名接受鲁索替尼治疗骨髓增殖性肿瘤的患者发生 Merkel 细胞癌，并与鳞状细胞癌和基底细胞癌碰撞。

JAAD Case Rep. 2024 Feb 2;45:98-101. doi: 10.1016/j.jdcr.2024.01.024. eCollection 2024 Mar.

Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.利用美国食品和药物管理局不良事件报告系统分析 Janus 激酶抑制剂与恶性皮肤肿瘤之间的关联。

Int J Clin Pharm. 2023 Dec;45(6):1483-1491. doi: 10.1007/s11096-023-01634-5. Epub 2023 Aug 22.

Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.肿瘤学中使用的靶向治疗的皮肤毒性：临床表现与管理的文献综述

Int J Womens Dermatol. 2021 Sep 28;7(5Part A):615-624. doi: 10.1016/j.ijwd.2021.09.009. eCollection 2021 Dec.

Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma.皮肤鳞状细胞癌的生物学特性与治疗进展

Cancers (Basel). 2021 Nov 11;13(22):5645. doi: 10.3390/cancers13225645.

Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.Janus 激酶抑制剂与非黑素瘤皮肤癌。

Curr Treat Options Oncol. 2021 Jan 9;22(2):11. doi: 10.1007/s11864-020-00815-y.

JAAD Case Rep. 2020 Jun 16;6(8):727-730. doi: 10.1016/j.jdcr.2020.06.008. eCollection 2020 Aug.

Int J Mol Sci. 2020 May 30;21(11):3900. doi: 10.3390/ijms21113900.

Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.抗肿瘤治疗引起的角化过度性皮肤不良反应：全面综述。

Drug Saf. 2020 May;43(5):395-408. doi: 10.1007/s40264-020-00907-6.

本文引用的文献

Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.接受JAK激酶抑制剂鲁索替尼治疗的患者发生侵袭性皮肤癌。

J Drugs Dermatol. 2017 May 1;16(5):508-511.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.COMFORT-II的长期研究结果，这是一项关于芦可替尼与最佳可用疗法治疗骨髓纤维化的3期研究。

Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23.

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib.在接受鲁索替尼治疗的患者中出现具有角化棘皮瘤样特征的爆发性鳞状细胞癌。

Br J Dermatol. 2015 Oct;173(4):1098-9. doi: 10.1111/bjd.13922. Epub 2015 Sep 1.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比

N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.

Ruxolitinib: a review of its use in patients with myelofibrosis.芦可替尼：在骨髓纤维化患者中的应用评价。

Drugs. 2015 Feb;75(3):297-308. doi: 10.1007/s40265-015-0351-8.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。

N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.

Iatrogenic immunosuppression and cutaneous malignancy.医源性免疫抑制与皮肤恶性肿瘤。

Clin Dermatol. 2011 Nov-Dec;29(6):602-13. doi: 10.1016/j.clindermatol.2011.08.009.

A new modality for immunosuppression: targeting the JAK/STAT pathway.免疫抑制的一种新方式：靶向JAK/STAT信号通路。

Nat Rev Drug Discov. 2004 Jul;3(7):555-64. doi: 10.1038/nrd1441.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验